GREM1 and Miyoshi myopathy: In the studies presented here, we demonstrated for the first time that the use of a Grem1-neutralizing antibody (UCB Pharma) in the 5TGM1/KaLwRij mouse model of MM resulted in a reduction of up to 81.2% in mean MM tumor burden.